13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
30 檔
24.4%
During the Q4 2024 filing period, Sector Gamma As (CIK: 0001475373) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $461.0M across 30 reported positions.
In Q4 2024, Sector Gamma As adopted a defensive or profit-taking posture, trimming 15 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | Stock-Healthcare | 10.53% | -1.99% | +40.85% | |
| 2 | MDT | Medtronic plc | Stock-Healthcare | 8.79% | +0.24% | -4.45% | |
| 3 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 7.12% | -2.78% | -39.18% | |
| 4 | GILD | Gilead Sciences Inc | Stock-Healthcare | 6.27% | -1.75% | EXIT | |
| 5 | BDX | Becton Dickinson And Co | Stock-Healthcare | 5.93% | -0.01% | -1.66% | |
| 6 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 5.00% | -0.67% | +29.92% | |
| 7 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 4.91% | +0.46% | +14.18% | |
| 8 | INCY | Incyte CORP | Stock-Healthcare | 4.69% | -0.26% | -23.78% | |
| 9 | AMGN | Amgen Inc | Stock-Healthcare | 4.12% | -1.86% | +187.50% | |
| 10 | JNJ | Johnson & Johnson | Stock-Healthcare | 3.88% | — | — | |
| 11 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.58% | -0.64% | -24.85% | |
| 12 | CNC | Centene CORP | Stock-Healthcare | 3.54% | +1.00% | +78.95% | |
| 13 | CVS | Cvs Health CORP | Stock-Healthcare | 3.35% | +1.19% | -28.15% | |
| 14 | BRKR | Bruker CORP | Stock-Healthcare | 3.20% | -0.18% | — | |
| 15 | QGEN | Qiagen N.V. | Stock-Healthcare | 3.12% | — | -8.57% | |
| 16 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.83% | +0.26% | +11.86% | |
| 17 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.52% | +0.05% | -6.74% | |
| 18 | ELV | Elevance Health Inc | Stock-Healthcare | 2.19% | +0.69% | -34.25% | |
| 19 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.90% | +0.56% | — | |
| 20 | BAX | Baxter International Inc | Stock-Healthcare | 1.59% | — | -58.79% | |
| 21 | BNTX | Biontech Se-adr | Stock-Other | 1.57% | — | — | |
| 22 | BIIB | Biogen Inc | Stock-Healthcare | 1.52% | -1.36% | -17.53% | |
| 23 | GEHC | GE Healthcare Technology | Stock-Healthcare | 1.34% | +0.77% | -53.14% | |
| 24 | HUM | Humana Inc | Stock-Healthcare | 1.22% | -0.79% | EXIT | |
| 25 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 1.15% | — | — | |
| 26 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.01% | +0.56% | — | |
| 27 | THC | Tenet Healthcare CORP | Stock-Healthcare | 0.95% | — | -16.54% | |
| 28 | TNDM 1.5 05-01-25Bond | Tandem Diabetes Care Inc | Bond | 0.82% | — | — | |
| 29 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.79% | -1.67% | EXIT | |
| 30 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.54% | — | +25.11% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | +3.9% | NEW | New buy |
| 2 | PFE | Pfizer Inc | +3.3% | +40.85% | Add |
| 3 | AMGN | Amgen Inc | +2.6% | +187.50% | Add |
| 4 | ZBH | Zimmer Biomet Holdings Inc | +1.5% | +29.92% | Add |
| 5 | CNC | Centene CORP | +1.4% | +78.95% | Add |
| 6 | ELAN | Elanco Animal Health Inc | +1.2% | NEW | New buy |
| 7 | PTCT | Ptc Therapeutics Inc | +1% | NEW | New buy |
| 8 | BMRN | Biomarin Pharmaceutical Inc | +0.9% | +14.18% | Add |
| 9 | TNDM 1.5 05-01-25Bond | Tandem Diabetes Care Inc | +0.8% | NEW | New buy |
| 10 | EW | Edwards Lifesciences CORP | +0.4% | -6.74% | Trim |
| 11 | BDX | Becton Dickinson And Co | +0.3% | -1.66% | Trim |
| 12 | IONS | Ionis Pharmaceuticals Inc | +0.3% | +11.86% | Add |
| 13 | BIO | Bio-rad Laboratories-a | +0.2% | — | Unchanged |
| 14 | BNTX | Biontech Se-adr | +0.1% | — | Unchanged |
| 15 | HUM | Humana Inc | +0.1% | +16.67% | Add |
| 16 | QGEN | Qiagen N.V. | 0% | -8.57% | Trim |
| 17 | LEGN | Legend Biotech Corp-adr | 0% | +25.11% | Add |
| 18 | BRKR | Bruker CORP | -0.1% | — | Unchanged |
| 19 | LNTH | Lantheus Holdings Inc | -0.3% | -18.92% | Trim |
| 20 | CAH | Cardinal Health Inc | -0.4% | -24.85% | Trim |
| 21 | MDT | Medtronic plc | -0.4% | -4.45% | Trim |
| 22 | THC | Tenet Healthcare CORP | -0.4% | -16.54% | Trim |
| 23 | INCY | Incyte CORP | -0.5% | -23.78% | Trim |
| 24 | BIIB | Biogen Inc | -0.6% | -17.53% | Trim |
| 25 | ALKS | Alkermes plc | -0.9% | EXIT | Sold out |
| 26 | AGIO | Agios Pharmaceuticals Inc | -0.9% | EXIT | Sold out |
| 27 | GILD | Gilead Sciences Inc | -1.1% | -31.70% | Trim |
| 28 | UHS | Universal Health Services-b | -1.2% | EXIT | Sold out |
| 29 | GEHC | GE Healthcare Technology | -1.7% | -53.14% | Trim |
| 30 | ELV | Elevance Health Inc | -2% | -34.25% | Trim |
| 31 | BMY | Bristol-myers Squibb Co | -2.3% | -39.18% | Trim |
| 32 | CVS | Cvs Health CORP | -2.4% | -28.15% | Trim |
| 33 | BAX | Baxter International Inc | -2.9% | -58.79% | Trim |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 30 disclosed positions in Q4 2024.
During Q4 2024, Sector Gamma As's top holdings by market value included PFE (10.5%)、MDT (8.8%)、BMY (7.1%). The largest single position, PFE, represented 10.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PFE, MDT, BMY) accounted for 24.4% of total reported equity market value during Q4 2024.
Top New Position Initiated
JNJ
市值: $11.3M
Top Position Liquidated / Trimmed
UHS
前期市值: $4.0M
In Q4 2024, Sector Gamma As made 30 total portfolio adjustments, initiating 4 new buys, adding to 8 positions, trimming 15 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.